AABB is the global leader in standards development, accreditation and implementation of quality systems in transfusion medicine and cellular therapies. AABB has an unwavering focus on donor and patient safety. We accomplish this by translating knowledge into solutions that shape the field of transfusion medicine and cellular therapies. AABB brings together those engaged in transfusion medicine and cellular therapies. AABB creates a unique learning environment, including our signature Annual Meeting, that inspires and enables research, innovation, discovery and excellence.
The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) was established in 1992. Operating under the auspices of the Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), it records details of bone marrow, peripheral blood and cord blood stem cell transplants throughout Australia and New Zealand.
In order to encourage activity in the medical and scientific field of blood and marrow transplantation in Africa, the African Blood and Marrow Transplantation Society (AfBMT) has been established with the support of the WBMT. The main objectives are to improve awareness among health workers, to improve the skills of healthcare teams through sharing experiences, and adapt the knowledge and potential of HSCT therapy to local resources and needs.
The Asia Pacific Blood and Marrow Transplantation Group (APBMT) is an international organization which is involved in hematological stem cell transplantation, sharing their information and cooperating with basic and clinical research in Asia-Pacific countries. APBMT is comprised of 22 countries/regions (Australia, Bangladesh, Cambodia, China, Hong Kong, India, Indonesia, Iran, Japan, Korea, Malaysia, Mongolia, Myanmar, Nepal, New Zealand, Pakistan, The Philippines, Singapore, Sri Lanka, Taiwan, Thailand and Vietnam) and is expanding its activities through the annual congresses, registration systems and working groups under the collaboration with the member societies of WBMT.
The American Society for Apheresis (ASFA) is the premier organization of physicians, scientists, and allied health professionals whose mission is to advance apheresis medicine for patients, donors, and practitioners through education, evidence-based practice, research, and advocacy. ASFA creates guidelines for the appropriate use of apheresis techniques, provides education for apheresis practitioners, and promotes research in apheresis medicine, as well as provides information for patients regarding apheresis procedures.
The American Society for Histocompatibility and Immunogenetics (ASHI) is a not-for-profit association of clinical and research professionals including immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists and technologists. As a professional society involved in histocompatibility, immunogenetics and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics; providing a forum for the exchange of information; and advocating the highest standards of laboratory testing in the interest of optimal patient care.
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 2,200 physicians, investigators and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of bone and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education and clinical practice in the field.
The CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide to increase survival and enrich quality of life for patients. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database. Our prospective and observational research is accomplished through scientific and statistical expertise, a large network of transplant centers and a clinical database of more than 500,000 patients. Support for the program is provided, in part, by grants and contracts from the National Institute of Health and Health Resources and Services Administration. Successful use of this funding has resulted in the completion of hundreds of studies that positively impact both clinical practice and transplant patients.
The EBMT is a collaborative peer network of professionals working, in centres and as individuals, in the field of clinical bone marrow transplantation and cellular therapy. Together, they make up the membership of our organization. Members contribute to and benefit from the collective knowledge that the EBMT has accrued, with the ultimate goal of saving the lives of patients with blood cancers and other life-threatening diseases.
EUROCORD is a non-profit organization affiliated to the University Paris Diderot and to the Assistance Publique des Hopitaux de Paris (APHP). It has strong links with the University Institute of Hematology (IUH) at the Saint-Louis hospital, and the French Agence de la biomédecine. Located within the campus of Saint Louis hospital in Paris, EUROCORD is a clinical research group (EUROCORD – study group) dedicated to study cord blood transplantation and innovative therapy in both malignant and non-malignant diseases, and to develop new indications for stem cell therapy. MONACORD is a branch of EUROCORD-Study housed at the Centre Scientifique de Monaco (CSM); It promotes studies to the better understanding and treatment of sickle cell disease. EUROCORD have recently extended its activity to develop new indications for innovative therapy in Autoimmune diseases and inflammatory disorders using non-hematopoietic stem cells from cord blood and placenta.
EFI is a European society of workers in the field of immunogenetics, histocompatibility testing and transplantation. EFI supports the development in Europe as a discipline in medicine and promote research and training in this field.
The objective of the European LeukemiaNet is to integrate the leading leukemia trial groups (CML, AML, ALL, CLL, MDS, CMPD), their interdisciplinary partners (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a cooperative network for advancements in leukemia-related research and health care and cure.
The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group was established in 2008 as a cooperative platform for physicians, scientists and healthcare workers from institutions in the WHO designated Eastern Mediterranean area with the goal of sharing experience, initiation of cooperative trials and establish common strategy to achieve optimization in the field of HSCT. The group's aim is to promote all aspects of patient care, academic and research activities associated with hematopoietic stem cell transplantation (HSCT) in the region which includes knowledge of the trends, patterns and status of the hematopoietic stem cell transplantation in Eastern Mediterranean (EM) countries.
Initiated in 1992 as a European Union Project in the 3rd Framework Programme "Advanced Informatics in Medicine (AIM)", the European Marrow Donor Information System (EMDIS) has become the standard platform for computer-based registry communication today. The aim of EMDIS is to establish a single virtual international donor registry allowing search coordinators to get the same information and services on international donors as accurately, timely and easily as from their own national donors. The scope of operation covers all aspects of an unrelated donor search from the preliminary search to the donor workup. Technically, EMDIS defines an open specification of a protocol for the electronic communication among registries. Therefore, EMDIS is implemented as an asynchronous peer-to-peer network connecting distributed, heterogeneous databases. Membership of EMDIS is free of charge. The community provides documentation, status information, software tools, support and a project management platform.
The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH Conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in Haematology.
The FACT Standards promote improvement and progress in cellular therapy and regenerative medicine. Meeting these requirements demonstrates a commitment to controlling every aspect that impacts the quality of products and therapeutic care. With regular updates through the collaboration of the most knowledgeable minds in cellular therapy, the depth and breadth of FACT Standards are unmatched. These international requirements instill confidence in cellular therapy products from FACT accredited organizations around the world.
The International Society of Blood Transfusion (ISBT) is a scientific society that was founded in 1935. Since that time the ISBT has grown in to an international society where transfusion medicine professionals from across the globe come together and do the one thing they do best: share knowledge to improve the safety of blood transfusion worldwide. We believe that with the power of knowledge we can improve the safety of blood transfusion worldwide. Professionals from over 100 countries already share their knowledge with this international transfusion medicine community by being a member of ISBT.
ISBT 128 is a global standard for the identification, labeling, and information transfer of medical products of human origin (including blood, cells, tissues, milk, and organ products) across international borders and disparate health care systems. The standard has been designed to ensure the highest levels of accuracy, safety, and efficiency for the benefit of donors, patients, and ISBT 128 licensed facilities worldwide. Featuring a unique, highly flexible, and comprehensive coding method for every collected product, ISBT 128 provides international consistency to support the transfer, transfusion, or transplantation of medical products of human origin.
ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients' lives. ISCT Members gain access to an influential global community of peers, experts, and organizations invested in cell therapy. ISCT offers a unique collaboration between academia, regulatory bodies, and industry partners in cell therapy translation.
JACIE develops and maintain global standards for the provision of quality medical and laboratory practice in cellular therapy. Based on these standards, JACIE offers accreditation to transplant programs in order to encourage health institutions and facilities to establish and maintain quality management systems impacting on all aspects of their activities and to engage in continuous improvement.
Promote excellence in hematopoietic stem cell transplantation (HSCT), stem cell donation, cellular therapy (CT) and accreditation in Latin America through collaboration of existing national and international societies using coordination, communication and advocacy. The purpose of this cooperation is to engage exclusively in charitable, scientific, and educational activities and endeavors including specifically, but not limited to, promoting and fostering, among the many scientific and clinical disciplines, the exchange and diffusion of information and ideas relating to SCT and CT and encouraging investigations on these matters. The focus of the Group is to collaboratively advance the field of HSCT and CT while not pre-empting the activities of its member societies.
WMDA strives that patients worldwide have equal access to high quality cells for transplantation from donors whose rights and safety are protected. Through its mission, WMDA promotes global collaboration and the sharing of best practices between its members for the benefit of stem cell donors and patients. Our aims: Optimising ‘Search, Match & Connect’: Provide a global platform that facilitates access to the most suitable stem cell source for a transplant patient; Supporting global development: Support members to develop and grow, so that more transplant patients find the most suitable match; Promoting donor care: Assure that the rights and safety of stem cell donors are promoted and protected; Ensuring quality: Promote product quality and global collaboration through accreditation and standardisation.